United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting "nibrozetone" as New Generic Name for EpicentRx's Lead Small Molecule NLRP3 Inhibitor NLRP3 Inhibitor, RRx-001

2023-07-06

临床3期快速通道

-New USAN name, a shortening of its chemical name, signifies a novel therapeutic class

-Novel generic name highlights the anti-inflammatory, anticancer, and antioxidant properties of RRx-001 and its potential to address several diverse unmet therapeutic needs

TORREY PINES, Calif., July 6, 2023 /PRNewswire/ -- EpicentRx, Inc., a clinical stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, today announced that the United States Adopted Name (USAN) Council in consultation with the World Health Organization's (WHO) International Nonproprietary Names (INN) Expert Committee has assigned the generic name "nibrozetone", a shortening of the chemical name, alpha-bromodinitroazetidine, for its lead drug candidate, RRx-001.

This is the first representative of a novel class of hypoxia-activated therapeutics with a chemical scaffold, a dinitroazetidine, that is commonly found only in explosives. RRx-001 is protective under normal oxygen conditions but under low oxygen conditions that are present in tumors the molecule transforms to metabolites that disrupt the tumor microenvironment. RRx-001 is under development for the treatment of small cell lung cancer (SCLC) in a Phase 3 clinical trial, and a soon-to-start late-stage trial for the protection against oral mucositis in first line head and neck cancer, an indication for which RRx-001 has received FDA Fast Track designation. RRx-001 is proprietary to EpicentRx with issued and currently pending patents that are expected to extend coverage until 2042.

"We are pleased but not surprised given its unique aerospace-derived origins and dual mechanism of action that USAN has recognized the first-in-class nature of RRx-001 with a new generic name," stated EpicentRx's CEO Dr. Tony Reid. "This is on the critical path for bringing a new drug to market and comes at an opportune time for EpicentRx given the late-stage trials with RRx-001 in SCLC, head and neck cancer, and radioprotection."

A nonproprietary name also known as a generic name is necessary and important, according to WHO, for "clear identification, safe prescription and dispensing of medicines to patients, and for communication and exchange of information among health professionals and scientists worldwide". To prevent potentially lethal clinical mix-ups, this name must be distinctive enough to clearly differentiate it from other medications. A multisyllabic mouthful, the chemically descriptive—and distinctive— nibrozetone is unlikely to be confused with other drug names. Therefore, and henceforth, EpicentRx will use "nibrozetone" in upcoming publications, press releases, forums, conferences, and other events or activities on the way to commercialization at which time, hopefully, a more mellifluous and shorter proprietary brand name will replace it.

About EpicentRx, Inc.

EpicentRx Incorporated is a privately held biopharmaceutical company with two innovation-driven platforms, of which RRx-001 and AdAPT-001 are the lead compounds, respectively. The company's mission, vision and strategy are to discover and develop novel, well-tolerated therapies that target a diverse range of unmet needs in in cancer and non-cancer indications. RRx-001, a dual mechanism small molecule, is designed and currently under clinical investigation to preferentially target diseased tissues like tumors even as it shields normal cells from harm. It is in a Phase 3 trial called REPLATINUM for the treatment of small cell lung cancer (SCLC). A soon-to-start trial is KEVLARx for protection against chemoradiation-induced oral mucositis in first line head and neck cancer.

Media Contact

Oliwia Barteczko

(908) 234-9900

SOURCE EpicentRx, Inc.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构